Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies

References

• Soriano JB, Cosio BG, Lopez-Campos JL, Soler-Cataluna JJ, Ancochea J; en nombre del Comite Cientifico Big C. Chronic obstructive pulmonary disease and big data. Arch Bronconeumol. 2021;57(2):144. doi:10.1016/j.arbres.2020.03.029
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Morena D, Gonzalez Y, et al. Clinical management of COPD in a real-world setting. a big data analysis. Arch Bronconeumol. 2021;57(2):94–100. doi:10.1016/j.arbres.2019.12.025
   PubMed Web of Science ®Google Scholar
• Cabrera Lopez C, Gomez Saenz JT, Molina Paris J, Trigueros Carrero JA, Lopez-Campos JL. Enabling a community approach to respiratory diseases: the HACER COPD project. Arch Bronconeumol. 2020.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Rodriguez DA, Quintana-Gallego E, Martinez-Llorens J, Carrasco Hernandez L, Barreiro E. Ten research questions for improving COPD care in the next decade. COPD. 2019;16(5–6):311–320. doi:10.1080/15412555.2019.1668919
   PubMedGoogle Scholar
• Halpin DMG, Criner GJ, Papi A, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24–36. doi:10.1164/rccm.202009-3533SO
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. Arch Bronconeumol (Engl Ed). 2021:S0300-2896(21)00103-4. doi:10.1016/j.arbres.2021.03.005.
   Google Scholar
• Carrasco Hernandez L, Caballero Eraso C, Ruiz-Duque B, et al. Deconstructing phenotypes in COPD: an analysis of the TRACE cohort. Arch Bronconeumol. 2021. doi:10.1016/j.arbres.2020.12.010
   Web of Science ®Google Scholar
• Lopez-Campos JL, Centanni S. current approaches for phenotyping as a target for precision medicine in COPD management. COPD. 2018;15(2):108–117. doi:10.1080/15412555.2018.1443064
   PubMedGoogle Scholar
• Ancochea J, Soriano JB. COPD in Spain at the start of a new decade. Arch Bronconeumol. 2020.
   Web of Science ®Google Scholar
• Marott JL, Ingebrigtsen TS, Colak Y, Vestbo J, Lange P. Lung function trajectories leading to chronic obstructive pulmonary disease as predictors of exacerbations and mortality. Am J Respir Crit Care Med. 2020;202(2):210–218. doi:10.1164/rccm.201911-2115OC
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa1105482
   PubMed Web of Science ®Google Scholar
• Mahan V. Clinical trial phases. Int J Clin Med. 2014;05:1374–1383. doi:10.4236/ijcm.2014.521175
   Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. doi:10.1081/COPD-200053377
   PubMedGoogle Scholar
• Sedgwick P. Understanding the ecological fallacy. BMJ. 2015;351:h4773. doi:10.1136/bmj.h4773
   PubMedGoogle Scholar
• Oude Rengerink K, Thangaratinam S, Barnfield G, et al. How can we teach EBM in clinical practice? An analysis of barriers to implementation of on-the-job EBM teaching and learning. Med Teach. 2011;33(3):e125–130. doi:10.3109/0142159X.2011.542520
   PubMed Web of Science ®Google Scholar
• Abad-Arranz M, Moran-Rodriguez A, Mascaros Balaguer E, et al. Community Assessment of COPD Health Care (COACH) study: a clinical audit on primary care performance variability in COPD care. BMC Med Res Methodol. 2018;18(1):68. doi:10.1186/s12874-018-0528-4
   PubMedGoogle Scholar
• Lopez-Campos JL, Navarrete BA, Soriano JB, et al. Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. Int J Chron Obstruct Pulmon Dis. 2018;13:2279–2288. doi:10.2147/COPD.S160842
   PubMed Web of Science ®Google Scholar
• Calle Rubio M, Alcazar navarrete B, Soriano JB, et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. Int J Chron Obstruct Pulmon Dis. 2017;12:417–426. doi:10.2147/COPD.S124482
   PubMed Web of Science ®Google Scholar
• Fernandez-Villar A, Fernandez-Garcia S, Represas-Represas C. Is the social component of chronic obstructive pulmonary disease a treatable trait? Arch Bronconeumol. 2020;56(4):199–200. doi:10.1016/j.arbr.2019.06.016
   PubMed Web of Science ®Google Scholar
• Fernandez-Villar A, Soriano JB, Lopez-Campos JL. Overdiagnosis of COPD: precise definitions and proposals for improvement. Br J Gen Pract. 2017;67(657):183–184. doi:10.3399/bjgp17X690389
   PubMed Web of Science ®Google Scholar
• Schermer TR, Robberts B, Crockett AJ, et al. Should the diagnosis of COPD be based on a single spirometry test? NPJ Prim Care Respir Med. 2016;26:16059. doi:10.1038/npjpcrm.2016.59
   PubMed Web of Science ®Google Scholar
• Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014;44(2):341–350. doi:10.1183/09031936.00216013
   PubMed Web of Science ®Google Scholar
• Nakawah MO, Hawkins C, Barbandi F. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. J Am Board Fam Med. 2013;26(4):470–477. doi:10.3122/jabfm.2013.04.120256
   PubMed Web of Science ®Google Scholar
• Song JH, Lee CH, Kim DK, et al. Differences in prevalence of asthma-COPD overlap according to different criteria. Medicine (Baltimore). 2018;97(36):e12049. doi:10.1097/MD.0000000000012049
   PubMed Web of Science ®Google Scholar
• Fernandez-Villar A, Lopez-Campos JL. Mixed COPD-asthma phenotype: ACOS or CAOS? A reflection on recent guidelines and recommendations. Arch Bronconeumol. 2016;52(5):277–278. doi:10.1016/j.arbr.2016.03.002
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Novella L, Soler C, et al. Clinical characteristics and risk of exacerbations associated with different diagnostic criteria of asthma-COPD overlap. Arch Bronconeumol. 2020;56(5):282–290. doi:10.1016/j.arbr.2020.03.003
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ. GOLD in 2017: a view from the Spanish COPD guidelines (GesCOPD). Arch Bronconeumol. 2017;53(3):89–90. doi:10.1016/j.arbres.2017.01.001
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Monteagudo M, Solntseva I, Alcazar B. Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study. Arch Bronconeumol. 2021;57(1):13–20. doi:10.1016/j.arbres.2019.12.015
   PubMed Web of Science ®Google Scholar
• Albertson TE, Chenoweth JA, Pearson SJ, Murin S. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). Expert Opin Pharmacother. 2020;21(2):213–231. doi:10.1080/14656566.2019.1701656
   PubMed Web of Science ®Google Scholar
• Proboszcz M, Mycroft K, Paplinska-Goryca M, et al. Relationship between blood and induced sputum eosinophils, bronchial hyperresponsiveness and reversibility of airway obstruction in mild-to-moderate chronic obstructive pulmonary disease. COPD. 2019;16(5–6):354–361. doi:10.1080/15412555.2019.1675150
   PubMedGoogle Scholar
• Singh D, Wedzicha JA, Siddiqui S, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020;21(1):240. doi:10.1186/s12931-020-01482-1
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Tetzlaff K, Vogelmeier C, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(9):1219–1221. doi:10.1164/rccm.201612-2525LE
   PubMed Web of Science ®Google Scholar
• Shin SH, Park HY, Kang D, et al. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respir Res. 2018;19(1):134. doi:10.1186/s12931-018-0840-x
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Ruiz Rodriguez O, Conde Baena P, Romero Palacios PJ, Agusti A. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018;51(1):1701457. doi:10.1183/13993003.01457-2017
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Castellano Minan F, Santiago Diaz P, Ruiz Rodriguez O, Romero Palacios PJ. Alveolar and bronchial nitric oxide in chronic obstructive pulmonary disease and asthma-COPD overlap. Arch Bronconeumol. 2018;54(8):414–419. doi:10.1016/j.arbr.2018.06.007
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Calero-Acuna C, Marquez-Martin E, et al. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review. Int J Chron Obstruct Pulmon Dis. 2017;12:1867–1876. doi:10.2147/COPD.S132962
   PubMed Web of Science ®Google Scholar
• Huang TH, Hsiue TR, Lin SH, Liao XM, Su PL, Chen CZ. Comparison of different staging methods for COPD in predicting outcomes. Eur Respir J. 2018;51(3):1700577. doi:10.1183/13993003.00577-2017
   PubMed Web of Science ®Google Scholar
• Coton S, Vollmer WM, Bateman E, et al. Severity of airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD): proposal for a new classification. COPD. 2017;14(5):469–475. doi:10.1080/15412555.2017.1339681
   PubMedGoogle Scholar
• Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–162. doi:10.1164/rccm.200910-1500OC
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103. doi:10.1056/NEJMoa1008378
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Vestbo J, Singh D. Long-acting bronchodilators for chronic obstructive pulmonary disease: which one(s), how, and when? Clin Chest Med. 2020;41(3):463–474. doi:10.1016/j.ccm.2020.05.005
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Sliwinski P, Rhee CK, et al. Changes in control status of COPD over time and their consequences: a prospective international study. Arch Bronconeumol. 2021;57(2):122–129. doi:10.1016/j.arbres.2020.06.003
   PubMed Web of Science ®Google Scholar
• Koreny M, Demeyer H, Benet M, et al. Patterns of physical activity progression in patients with COPD. Arch Bronconeumol. 2020.
   PubMed Web of Science ®Google Scholar
• Plaza V, Fernandez C, Curto E, et al. Therapeutic adherence of COPD patients according to the involvement levels in health education in their centers. Arch Bronconeumol. 2020.
   Web of Science ®Google Scholar
• Calle Rubio M, Lopez-Campos JL, Soler-Cataluna JJ, et al. Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study. Respir Res. 2017;18(1):200. doi:10.1186/s12931-017-0685-8
   PubMedGoogle Scholar
• Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65–74. doi:10.1016/j.rmed.2016.01.001
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518–2533. doi:10.1007/s12325-017-0626-4
   PubMed Web of Science ®Google Scholar
• Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–730. doi:10.2147/COPD.S102494
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–479. doi:10.1136/thx.2009.125435
   PubMed Web of Science ®Google Scholar
• Postma DS, Roche N, Colice G, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:1163–1186. doi:10.2147/COPD.S68289
   PubMed Web of Science ®Google Scholar
• Paneroni M, Simonelli C, Vitacca M, Ambrosino N. Aerobic exercise training in very severe chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2017;96(8):541–548. doi:10.1097/PHM.0000000000000667
   PubMed Web of Science ®Google Scholar
• Moore E, Newson R, Joshi M, et al. Effects of pulmonary rehabilitation on exacerbation number and severity in people with COPD: an historical cohort study using electronic health records. Chest. 2017;152:1188–1202. doi:10.1016/j.chest.2017.05.006
   PubMed Web of Science ®Google Scholar
• Maddocks M, Delogu V, Jones SE, Polkey MI, Man WD. Exercise training versus neuromuscular stimulation in severe chronic obstructive pulmonary disease. Arch Bronconeumol. 2017;53(7):357–359. doi:10.1016/j.arbres.2016.11.022
   PubMed Web of Science ®Google Scholar
• Raskin J, Marks T, Miller A. Phenotypes and characterization of COPD: a pulmonary rehabilitation perspective. J Cardiopulm Rehabil Prev. 2017.
   Web of Science ®Google Scholar
• Barreiro E. Skeletal muscle dysfunction in COPD: novelties in the last decade. Arch Bronconeumol. 2017;53(2):43–44. doi:10.1016/j.arbres.2016.07.009
   PubMed Web of Science ®Google Scholar
• Pleguezuelos E, Guirao L, Moreno E, et al. Safety of rehabilitation program for COPD patients. Arch Bronconeumol. 2017;54:111–112. doi:10.1016/j.arbres.2017.06.012
   PubMed Web of Science ®Google Scholar
• Wouters EFM, Wouters B, Augustin IML, Houben-Wilke S, Vanfleteren L, Franssen FME. Personalised pulmonary rehabilitation in COPD. Eur Respir Rev. 2018;27:147. doi:10.1183/16000617.0125-2017
   Web of Science ®Google Scholar
• Milner SC, Boruff JT, Beaurepaire C, Ahmed S, Janaudis-Ferreira T. Rate of, and barriers and enablers to, pulmonary rehabilitation referral in COPD: a systematic scoping review. Respir Med. 2018;137:103–114. doi:10.1016/j.rmed.2018.02.021
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-4
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/olodaterol decreases exacerbation rates compared with tiotropium in a range of patients with COPD: pooled analysis of the TONADO((R))/DYNAGITO((R)) trials. Adv Ther. 2020;37(10):4266–4279. doi:10.1007/s12325-020-01438-3
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. doi:10.1016/S2213-2600(13)70052-3
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Miralles C. Exacerbation syndrome in COPD: a paradigm shift. Arch Bronconeumol. 2020.
   Web of Science ®Google Scholar
• Lee L, Kerwin E, Collison K, et al. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: a randomised, 3-phase study. Respir Med. 2017;131:148–157. doi:10.1016/j.rmed.2017.08.013
   PubMed Web of Science ®Google Scholar
• Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, Lee YC. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J. 2009;33(4):778–784. doi:10.1183/09031936.00115308
   PubMed Web of Science ®Google Scholar
• Um SW, Yoo CG, Kim YW, Han SK, Shim YS. The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci. 2007;22(5):839–845. doi:10.3346/jkms.2007.22.5.839
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Carrasco-Hernandez L, Roman Rodriguez L, Quintana-Gallego E, Carmona Bernal C, Alcazar Navarrete B. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol. 2020;56(4):242–248. doi:10.1016/j.arbr.2020.02.002
   PubMed Web of Science ®Google Scholar
• Celli B, Divo M, Plata VP. Pharmacotherapy impacts on COPD mortality. Arch Bronconeumol. 2021;57(1):5–6. doi:10.1016/j.arbres.2020.03.030
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Ruiz-Duque B, Carrasco-Hernandez L, Caballero-Eraso C. Integrating comorbidities and phenotype-based medicine in patient-centered medicine in COPD. J Clin Med. 2020;9(9):2745. doi:10.3390/jcm9092745
   PubMed Web of Science ®Google Scholar
• de la Rosa Carrillo D, Lopez-Campos JL, Alcazar Navarrete B, et al. Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. Arch Bronconeumol. 2020;56(10):651–664. doi:10.1016/j.arbres.2020.04.023
   PubMed Web of Science ®Google Scholar
• Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013;107(1):10–22. doi:10.1016/j.rmed.2012.10.024
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Miravitlles M, de la Rosa Carrillo D, Canton R, Soler-Cataluna JJ, Martinez-Garcia MA. Current challenges in chronic bronchial infection in patients with chronic obstructive pulmonary disease. J Clin Med. 2020;9(6):1639. doi:10.3390/jcm9061639
   PubMed Web of Science ®Google Scholar
• Lujan M, Ergan B. Guidelines for chronic non-invasive ventilation in COPD: from experience to evidence. Arch Bronconeumol. 2020.
   PubMed Web of Science ®Google Scholar
• Cruthirds CL, van der Meij BS, Wierzchowska-McNew A, Deutz NEP, Engelen M. Presence or absence of skeletal muscle dysfunction in chronic obstructive pulmonary disease is associated with distinct phenotypes. Arch Bronconeumol. 2020;57:264–272. doi:10.1016/j.arbres.2019.12.034
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Caballero-Eraso C, Barrot-Cortes E. Home mechanical ventilation for stable COPD in GOLD 2017: what are we ventilating? Respirology. 2017;22(8):1497–1499. doi:10.1111/resp.13091
   PubMed Web of Science ®Google Scholar
• Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32(3):796–803. doi:10.1183/09031936.00126107
   PubMed Web of Science ®Google Scholar
• Ecenarro PS, Iguiniz MI, Tejada SP, et al. Management of COPD in end-of-life care by Spanish pulmonologists. COPD. 2018;15(2):171–176. doi:10.1080/15412555.2018.1441274
   PubMedGoogle Scholar
• Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55(12):1000–1006. doi:10.1136/thorax.55.12.1000
   PubMed Web of Science ®Google Scholar
• Au DH, Udris EM, Fihn SD, McDonell MB, Curtis JR. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Arch Intern Med. 2006;166(3):326–331. doi:10.1001/archinte.166.3.326
   PubMedGoogle Scholar
• van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166(10):1358–1363. doi:10.1164/rccm.200206-512OC
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60(6):480–487. doi:10.1136/thx.2004.034280
   PubMed Web of Science ®Google Scholar
• Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology. Respir Res. 2011;12(1):107. doi:10.1186/1465-9921-12-107
   PubMedGoogle Scholar
• Rossi A, Guerriero M, Corrado A; Group OAS. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77. doi:10.1186/1465-9921-15-77
   PubMed Web of Science ®Google Scholar
• Greulich T, Kostikas K, Gaga M, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018;13:1229–1237. doi:10.2147/COPD.S159732
   PubMed Web of Science ®Google Scholar
• Magnussen H, Watz H, Kirsten A, et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med. 2014;108(4):593–599. doi:10.1016/j.rmed.2014.01.002
   PubMed Web of Science ®Google Scholar
• Schermer TR, Hendriks AJ, Chavannes NH, et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J. 2004;13(1):48–55. doi:10.1016/j.pcrj.2003.11.005
   PubMedGoogle Scholar
• Liesker JJ, Bathoorn E, Postma DS, Vonk JM, Timens W, Kerstjens HA. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med. 2011;105(12):1853–1860. doi:10.1016/j.rmed.2011.07.002
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-4
   PubMed Web of Science ®Google Scholar
• Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(9):CD009039.
   PubMed Web of Science ®Google Scholar